Rubin Jonathan's Form 4 filing
Supernus Pharmaceuticals, Inc. (SUPN) · filed Feb 24, 2025
- Accession no.
- 0001628280-25-007532
- Filed
- Feb 24, 2025
- Trade date
- Feb 21-23, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $36.3K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rubin JonathanCIK 0001836067 | Officer (SVP, Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 21, 2025 | Common Stock | MOption exerciseAcquired | +1,875 | $0.00 | $0 | 8,780 | Direct | |
| Feb 21, 2025 | Common Stock | SSaleDisposed | −927 | $39.15 | −$36,292.05 | 7,853 | Direct | |
| Feb 22, 2025 | Common Stock | AGrant or awardAcquired | +750 | $0.00 | $0 | 8,603 | Direct | |
| Feb 22, 2025 | Common Stock | AGrant or awardAcquired | +1,250 | $0.00 | $0 | 9,853 | Direct | |
| Feb 23, 2025 | Common Stock | AGrant or awardAcquired | +1,250 | $0.00 | $0 | 11,103 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 21, 2025 | Common Stock | MOption exerciseDisposed | −1,875 | $0.00 | $0 | 0 | Direct | |
| Feb 22, 2025 | Common Stock | DReturned to the companyDisposed | −750 | $0.00 | $0 | 750 | Direct | |
| Feb 22, 2025 | Common Stock | DReturned to the companyDisposed | −1,250 | $0.00 | $0 | 3,750 | Direct | |
| Feb 23, 2025 | Common Stock | DReturned to the companyDisposed | −1,250 | $0.00 | $0 | 2,500 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.